First use of CRISPR to substitute genes to treat patients with cancer


For the first time, scientists have used CRISPR technology to insert genes that allow immune cells to focus their attack on cancer cells, potentially leaving normal cells unharmed and increasing the effectiveness of immunotherapy. The new approach is being presented today at the Society for Immunotherapy of Cancer (SITC) 2022 and is being published in the journal Nature. It is co-led by Antoni Ribas, MD, Ph.D., of UCLA Jonsson Comprehensive Cancer Center and professor of medicine at UCLA.

Picking the fastest progressing patients to speed Parkinson’s disease clinical trials

Previous article

How to Shape a Better Workplace Environment for Your Startup

Next article

You may also like


Leave a reply

Your email address will not be published. Required fields are marked *

More in Innovations